On
Aug. 28 of last year Kimberley Yout, 45, was diagnosed with a rare
brain infection that developed as a side effect of Tysabri, a drug she
took for six years to keep her MS in check. Yout’s speech became
slurred, her gait unsteady, and her future uncertain. Now, she is suing
the two companies that marketed Tysabri — Biogen Idec Inc. of Weston and
the Irish drug maker Elan Pharmaceuticals Inc.
The lawsuit is one of at least a half-dozen pending in Massachusetts and federal courts in three other states. In each case, plaintiffs are seeking more than $1 million in punitive damages from Biogen Idec and Elan on behalf of patients or their families. After taking Tysabri, the patients developed progressive multifocal leukoencephalopathy, known as PML, an infection of the brain’s white matter that can cause death or severe disability. Her complaint, filed Friday, alleges they failed to adequately warn patients of the risks some face from prolonged use of Tysabri.more
Multiple Sclerosis Appears to Originate in Different Part of Brain ...
News from Rutgers
The search for the cause of multiple sclerosis, a debilitating disease that affects up to a half million people in the United States, has confounded researchers and ...
Does robot-assisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized-control trial.
Interactions of environment and genes in multiple sclerosis.
MS susceptibility is comprised of both genetic and environmental factors and it has become increasingly clear that these interact. The major histocompatiblity complex is the major site of the interactions which determine MS risk.
Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis
The lawsuit is one of at least a half-dozen pending in Massachusetts and federal courts in three other states. In each case, plaintiffs are seeking more than $1 million in punitive damages from Biogen Idec and Elan on behalf of patients or their families. After taking Tysabri, the patients developed progressive multifocal leukoencephalopathy, known as PML, an infection of the brain’s white matter that can cause death or severe disability. Her complaint, filed Friday, alleges they failed to adequately warn patients of the risks some face from prolonged use of Tysabri.more
Multiple Sclerosis Appears to Originate in Different Part of Brain ...
News from Rutgers
The search for the cause of multiple sclerosis, a debilitating disease that affects up to a half million people in the United States, has confounded researchers and ...
Does robot-assisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized-control trial.
Interactions of environment and genes in multiple sclerosis.
MS susceptibility is comprised of both genetic and environmental factors and it has become increasingly clear that these interact. The major histocompatiblity complex is the major site of the interactions which determine MS risk.
To
assess the relationships of sun exposure history, supplementation and
environmental factors to vitamin D levels in multiple
sclerosis (MS) patients and to
evaluate the associations between sun exposure and MRI measures.
Sun exposure may have direct effects on
MRI measures of neurodegeneration in MS, independently of vitamin D.
Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis
To determine whether the known higher prevalence of migraine in lower household (HH) income groups is explained by a higher
incidence rate or a lower remission rate.
The higher incidence of migraine in lower HH income groups is compatible
with the social causation hypothesis.
Severe Disability in Patients with Relapsing-Remitting Multiple Sclerosis Is Associated with Profound Changes in the Regulation of Leptin Secretion..
Randomized controlled trial of a behavioral intervention targeting symptoms and physical activity in multiple sclerosis.
We present a case of acute neuroborreliosis in the setting of long-term treatment with natalizumab. A 33-year-old man was
diagnosed with relapsing-remitting multiple sclerosis (MS) in 1999.
